Impact of vulvovaginal health on postmenopausal women: A review of surveys on symptoms of vulvovaginal atrophy

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 437-447

  Parish, Sharon J ^a   Nappi, Rossella E ^b   Krychman, Michael L ^c   Kellogg Spadt, Susan ^d   Simon, James A ^e   Goldstein, Jeffrey A ^f   Kingsberg, Sheryl A ^g  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Pelvic and Sexual Health Institute   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f NOVO NORDISK INC   (United States)

^g CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health care professional; Hypoactive sexual desire disorder; Local vaginal estrogen therapy; Quality of life; Urinary tract infection; Vulvovaginal atrophy

Indexed keywords

ESTROGEN; LUBRICATING AGENT;

DISEASE SEVERITY; DYSPAREUNIA; DYSURIA; ESTROGEN THERAPY; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEALTH CARE PERSONNEL; HEALTH PERSONNEL ATTITUDE; HUMAN; HUMAN RELATION; MEDICAL INFORMATION; MEDICAL TERMINOLOGY; NOCTURIA; PATIENT ATTITUDE; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SEXUAL HEALTH; SYMPTOM; SYSTEMIC THERAPY; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; VAGINA ATROPHY; VAGINA RING; VAGINAL DRYNESS; VAGINAL PRURITUS; VULVOVAGINAL DISCOMFORT;

EID: 84880943433     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S44579     Document Type: Review

References (45)

1. US Census Bureau. Statistical Abstract of the United States: 2012. Table 104. Expectation of Life at Birth, 1970 to 2008, and Projections, 2010 to 2020. Washington, DC: US Census Bureau; 2011. Available from: http://www.census.gov/compendia/statab/2012/tables/12s0105.pdf. Accessed April 6, 2012.
2. US Census Bureau. Statistical Abstract of the United States: 2012. Table 7. Resident Population by Sex and Age: 1980 to 2010. Washington, DC: US Census Bureau; 2011. Available from: http://www.census.gov/compendia/statab/2012/tables/12s0007.pdf. Accessed April 6, 2012.
3. Nichols HB, Trentham-Dietz A, Hampton JM, et al. From menarche to menopause: trends among US women born from 1912 to 1969. Am J Epidemiol. 2006;164(10):1003-1011.
4. Obermeyer CM, Reher D, Alcala LC, Price K. The menopause in Spain: results of the DAMES (Decisions At MEnopause) study. Maturitas. 2005;52(3-4):190-198.
5. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-2142.
6. Wyeth. REVEAL: Revealing Vaginal Effects at Mid-Life: Surveys of Postmenopausal Women and Health Care Professionals who Treat Postmenopausal Women. Madison, NJ: Wyeth; 2009. Available from: http://www.revealsurvey.com/pdf/reveal-survey-results.pdf. Accessed April 6, 2012.
7. Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67(3):233-238.
8. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views and Attitudes (VIVA) - results from an international survey. Climacteric. 2012;15(1):36-44.
9. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85(1):87-94.
10. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096.
11. Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women's Health Initiative. Menopause. 2011;18(11):1160-1171.
12. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3-1):357-369; quiz 370-371.
13. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23(3):259-263.
14. van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55(6):446-451.
15. Panay N, Maamari R. Treatment of postmenopausal vaginal atrophy with 10-μg estradiol vaginal tablets. Menopause Int. 2012;18(1):15-19.
16. Cumming GP, Currie HD, Moncur R, Lee AJ. Web-based survey on the effect of menopause on women's libido in a computer-literate population. Menopause Int. 2009;15(1):8-12.
17. Cumming GP, Herald J, Moncur R, Currie H, Lee AJ. Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int. 2007;13(2):79-83.
18. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause. 2008;15(4 Pt 1):661-666.
19. Simon JA, Komi J. Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships. Proceedings of the North American Menopause Society (NAMS); October 3-6, 2007; Dallas, TX, USA.
20. Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause. 2009;16(3):442-452.
21. Kingsberg S, Althof SE. Evaluation and treatment of female sexual disorders. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20 Suppl 1: S33-S43.
22. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25-40.
23. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther. 2002;28(4):317-330.
24. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.
25. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-774.
26. Rust J, Derogatis L, Rodenberg C, Koochaki P, Schmitt S, Golombok S. Development and validation of a new screening tool for hypoactive sexual desire disorder: The Brief Profile of Female Sexual Function (B-PFSF). Gynecol Endocrinol. 2007;23(11):638-644.
27. Nappi RE, Lello S, Melis GB, Albani F, Polatti F, Genazzani AR. LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause. Climacteric. 2009;12(6):533-540.
28. Schneidewind-Skibbe A, Hayes RD, Koochaki PE, Meyer J, Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J Sex Med. 2008;5(2):301-335.
29. Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women's Health Across the Nation (SWAN). Menopause. 2005;12(4):385-398.
30. Brown JS, Vittinghoff E, Kanaya AM, Agarwal SK, Hulley S, Foxman B; For Heart and Estrogen/Progestin Replacement Study Research Group. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol. 2001;98(6):1045-1052.
31. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072-1079.
32. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131.
33. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2009;(4):CD001405.
34. Wennberg AL, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol. 2009;55(4):783-791.
35. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt). 2009;18(4):461-468.
36. Nappi RE, Davis SR. The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric. 2012;15(3): 267-274.
37. Santen RJ, Allred DC, Ardoin SP, et al; For Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(7 Suppl 1):s1-s66.
38. Sturdee DW, Panay N; For International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010;13(6):509-522.
39. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257-271.
40. Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don't talk about when we don't talk about sex: results of a national survey of US obstetrician/gynecologists. J Sex Med. 2012;9(5):1285-1294.
41. Bachmann GA, Leiblum SR, Grill J. Brief sexual inquiry in gynecologic practice. Obstet Gynecol. 1989;73(3-1):425-427.
42. Sadovsky R, Alam W, Enecilla M, Cosiquien R, Tipu O, Etheridge Otey J. Sexual problems among a specific population of minority women aged 40-80 years attending a primary care practice. J Sex Med. 2006;3(5):795-803.
43. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci. 1997;314(4):228-231.
44. Beard MK. Atrophic vaginitis. Can it be prevented as well as treated? Postgrad Med. 1992;91(6):257-260.
45. Osmers R, Völksen M, Schauer A. Vaginosonography for early detection of endometrial carcinoma? Lancet. 1990;335(8705):1569-1571.